J & J; Profit Up, Mulls Guidant Options

Johnson & Johnson on Tuesday said its third-quarter earnings rose on strong demand for its medical devices, including its Cypher stent, but sales of prescription drugs fell amid competition from cheaper generics...

Take 1 minute to subscribe and you'll get this story immediately, plus: